drugset / Trial / NCT01303705
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall goal of promoting an immune response against prostate cancer.
Timeline
- Start
- 2010-10-14
- Primary completion
- 2016-07-05
- Completion
- 2016-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 900 mg/m2 | Intravenous |
| Subject | anti-OX40 | Monoclonal antibody | 0.4 mg/kg | Intravenous |